Ironwood Pharmaceuticals Enters Material Definitive Agreement

TL;DR

Ironwood Pharma just signed a big deal, filing an 8-K on 12/18/25.

AI Summary

On December 18, 2025, Ironwood Pharmaceuticals, Inc. entered into a material definitive agreement. The filing also indicates other events and includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This filing signals a significant new contract or partnership for Ironwood Pharmaceuticals, which could impact its future revenue and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks related to partnerships, obligations, or financial commitments.

Key Players & Entities

• IRONWOOD PHARMACEUTICALS, INC. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• Boston, Massachusetts (location) — Principal Executive Offices
• December 18, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ich registered Class A common stock, $0.001 par value IRWD Nasdaq Global Select M
• $12.5 m — provides for a payment by VectivBio of $12.5 million, in the aggregate, to Ferring, wi
• $7.5 million — to Ferring, with an initial payment of $7.5 million and a second payment of $5 million, pay
• $5 m — of $7.5 million and a second payment of $5 million, payable on or by December 31, 20

Filing Documents

• tm2534055d1_8k.htm (8-K) — 34KB
• tm2534055d1_ex10-1.htm (EX-10.1) — 57KB
• 0001104659-25-123974.txt ( ) — 265KB
• irwd-20251218.xsd (EX-101.SCH) — 3KB
• irwd-20251218_lab.xml (EX-101.LAB) — 33KB
• irwd-20251218_pre.xml (EX-101.PRE) — 22KB
• tm2534055d1_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. Amendment to License Agreement with Ferring On December 18, 2025, Ironwood Pharmaceuticals, Inc. (the "Company"), solely for purposes of a limited payment guarantee, VectivBio AG, a wholly owned subsidiary of the Company ("VectivBio"), and Ferring International Center S.A. ("Ferring"), entered into that certain third amendment (the "Amendment") to the amended and restated exclusive license agreement, dated as of December 6, 2016, as amended, by and between GlyPharma Therapeutic Inc. (as predecessor to VectivBio) and Ferring (the "Ferring License Agreement"). The Amendment provides for a payment by VectivBio of $12.5 million, in the aggregate, to Ferring, with an initial payment of $7.5 million and a second payment of $5 million, payable on or by December 31, 2026, subject to accelerated payment in certain circumstances as specified therein. In addition, a high single-digit percentage royalty on the net sales of any Licensed Product will be payable, on a Licensed-Product-by-Licensed Product (as defined in the Amendment) and country-by-country basis, by VectivBio for seven years from the first commercial sale of such Licensed Product. VectivBio is obligated to pay a low single-digit percentage royalty from the end of the seventh year from such first commercial sale through the date on which such Licensed Product ceases to be covered by a valid claim of a patent included in the Licensed Patents (as defined in the Ferring License Agreement) and the Contested Patents (as defined in the Amendment). The Amendment also includes certain other revisions, including to clarify ownership and certain other intellectual property rights . The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of such agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

01 Other Events

Item 8.01 Other Events. In connection with entry into the Amendment, on December 18, 2025, VectivBio and the Company entered into a settlement agreement and release pursuant to which VectivBio and Ferring have settled all claims between the parties arising out of Ferring's complaint captioned Ferring International Center S.A. v. VectivBio AG 2:25-cv-01001 brought in the United States District Court for the Eastern District of Texas .

01 Financial Statements and

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1* Third Amendment to the Amended and Restated Exclusive License Agreement dated as of December 18, 2025, by and among VectivBio AG and Ferring International Center S.A., and, solely for purposes of a limited payment guarantee, Ironwood Pharmaceuticals, Inc. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. * Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as the Company has determined they (1) are not material and (2) are the type that the Company treats as private or confidential. The Company hereby agrees to furnish a copy of any omitted portion to the Securities and Exchange Commission upon request.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 23, 2025 Ironwood Pharmaceuticals, Inc. By: /s/ Gregory Martini Name: Gregory Martini Title: Senior Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR